1-5 of 5
Andrew R. Pettitt, PhD MRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy

Chantal Hargreaves, PhD, Chisako Iriyama, MD PhD, Matthew JJ Rose-Zerilli, PhD, Charlotte Lee, BSc, Kathleen Potter, PhD, Rosalind Ganderton, Khiyam Hussain, Lee Machado, PhD, Edward Hollox, Sarah E Coupland, MBBS, PhD, Michael Stackpole, Melanie Oates, PhD, Andrew R. Pettitt, PhD MRCPath, Mark Cragg, PhD, Jonathan C Strefford, PhD
Journal: Blood
Blood (2014) 124 (21): 2996.
https://doi.org/10.1182/blood.V124.21.2996.2996
Published: 2014
Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 922.
https://doi.org/10.1182/blood.V116.21.922.922
Published: 2010
Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 697.
https://doi.org/10.1182/blood.V116.21.697.697
Published: 2010
Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock
Journal: Blood
Blood (2009) 114 (22): 3428.
https://doi.org/10.1182/blood.V114.22.3428.3428
Published: 2009
Journal Articles

Chronic Lymphocytic Leukaemia Patients with a Biallelic Deletion of 13q14 Have a More Favourable Profile of Prognostic Factors Compared with Cases That Have a Monoallelic 13q14 Deletion.

Andrew R. Pettitt, PhD, MRCPath, Chloe J. Emmens, Ke Lin, PhD, Robert J. Harris, PhD
Journal: Blood
Blood (2005) 106 (11): 5019.
https://doi.org/10.1182/blood.V106.11.5019.5019
Published: 2005